BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Psiron Ltd 

Level 1, 82 Waterloo Road

North Ryde  New South Wales  2113  Australia
Phone: 61-2-9889-1200 Fax: 61-2-9889-1288


View Clinical Trials from BioPharm Insight

Psiron Ltd (ASX: PSX) is focused on the development and commercialization of novel biological therapies for patients with cancer. Psiron's lead technology CAVATAK™ (coxsackievirus A21) is being developed in melanoma, breast and prostate cancer. Preliminary encouraging results have also been achieved in multiple myeloma. Early research using two other viruses is underway, echovirus-1 in ovarian and prostate cancers and coxsackievirus DAF variant in colorectal cancer.

Coxsackievirus and echovirus are oncolytic viruses that occur naturally and target specific and known sites on the outer surface of some cancer cells. Once locating these sites, the viruses proceed to destroy the cancer cells.

Psiron acquired the intellectual property rights to this technology, by licence, from ViroTarg Pty Ltd in August 2004.

Another wholly owned project is a therapy for treating skin diseases, currently in Phase II clinical trials. SORAFIN™, a combination of auranofin (synthetic gold) and a steroid, is in development for atopic dermatitis (eczema) and psoriasis. Psiron is currently seeking a commercialisation partner for its skin therapy treatment.

Psiron has made a number of investments in healthcare companies. These other investments, while having revenue potential, have their own management structures, enabling Psiron to provide oversight rather than daily involvement.

Psiron has a 50 per cent interest in Injet Digital Aerosols Limited (formerly known as Vapotronics Inc) to develop a drug inhalation device. This technology has been licensed to Canon Inc of Japan and clinical trials are planned. Additionally, Psiron owns 28.4 per cent of Analytica Ltd (ASX:ALT) specializing in the development, manufacture and marketing of medical devices; and 3.4 per cent of unlisted public company, CBio Ltd, who is developing chaperonin-10, a potential treatment for a number of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

Last Updated: 12-21-05

 Key Statistics

Ownership: Public

Web Site: Psiron Ltd
Symbol: PSX.AX


 Company News
Psiron Ltd (PSX.AX) CEO And CFO Resign 2/2/2006 11:06:33 AM    More...
Psiron Ltd (PSX.AX) Release: Breast, Prostate And Colorectal Cancer Research Milestones Achieved 1/23/2006 4:55:57 PM    More...
Psiron Ltd (PSX.AX) Release: GMP Manufacturing Facility 1/23/2006 4:49:20 PM    More...
Psiron Ltd (PSX.AX) Release: New Milestone Reached In ViroTarg Agreement: First Patient Into Clinical Trial In Melanoma 1/23/2006 4:38:00 PM    More...
Psiron Ltd (PSX.AX)'s Cavatak™ Receives Orphan Drug Designation From The FDA 1/23/2006 4:27:00 PM    More...
Anti Cancer Virotherapy Well Tolerated In First Human Administration, Research Finds 10/19/2005 5:13:00 PM    More...
Psiron Ltd Puts Back Cancer Trial Results 10/19/2005 5:12:18 PM    More...